SB1525 creates a new regulatory framework for electronic smoking devices and nicotine-containing e-liquids sold in Hawaii. It requires manufacturers to file annual certifications with the Department of Taxation confirming that each product has FDA marketing authorization, has a timely filed premarket tobacco product application still pending or otherwise protected by FDA/court action, or is exempt from needing a new application due to branding or packaging changes. The certification must list each brand, product name, category, and flavor, and must be accompanied by FDA-related documentation and a $250 fee per product.
The bill directs the department to maintain a public directory of approved manufacturers and products beginning October 1, 2025. Products not listed in the directory may not be sold in the state after the effective transition periods, and the bill authorizes seizure, forfeiture, and destruction of noncompliant products. It also establishes notice-and-cure procedures before removal from the directory, requires retailers and wholesalers to clear inventory within specified timeframes, and imposes escalating civil penalties, license suspensions, misdemeanor liability for false statements, and unfair trade practice consequences for repeat violations. Nonresident or foreign manufacturers must also appoint a U.S. agent for service of process and post a $25,000 bond unless already registered to do business in Hawaii.
The bill’s impact on state law is to add a detailed enforcement and compliance regime to Chapter 245 of the Hawaii Revised Statutes, with the Department of Taxation as the lead agency. It expands state oversight of vape and e-liquid sales, creates new reporting and inspection duties, and dedicates collected fees and penalties to administration and enforcement. It also requires annual reporting to the Legislature on the directory, revenues, expenditures, and enforcement activity, while preserving preexisting rights, duties, and proceedings that arose before the act’s effective date.
The general sentiment reflected in the bill materials is regulatory and public-health oriented, with the measure framed as a compliance and enforcement tool rather than a tax increase. No committee testimony or recorded votes were provided, so there is no documented floor or committee debate to gauge support or opposition. Based on the text alone, the bill appears designed to tighten control over vape products and align state retail access with federal FDA authorization status.
The main points of contention likely concern the burden on manufacturers and retailers, especially smaller businesses and out-of-state companies, because the bill imposes annual certification costs, directory compliance requirements, inventory sell-off deadlines, compliance checks, penalties, and bonding requirements. Another likely issue is the practical effect of limiting sales to products listed in the state directory, which could remove many products from the market and raise questions about enforcement, product availability, and administrative workload for the department.
SB1525 amends Chapter 245, Hawaii Revised Statutes, by adding a new section governing electronic smoking devices and nicotine-containing e-liquids. It gives the Department of Taxation authority to certify products, maintain a public directory of approved items, conduct compliance checks, impose penalties, and enforce removal and seizure of noncompliant products. The bill also creates new obligations for manufacturers, retailers, wholesalers, dealers, importers, and certain foreign manufacturers, including registration-related requirements and a surety bond for nonresident entities.
The bill appears generally supportive of stronger regulation of vaping products and youth-access controls, with its structure emphasizing FDA compliance, public listing, and enforcement. Because no committee transcripts or votes were provided, there is no direct record of debate, amendments, or partisan division. On the face of the text, the measure reads as a public-health and consumer-protection bill with a compliance-heavy approach.
Likely areas of contention include the cost and administrative burden on manufacturers, especially the $250 per-product annual certification fee, the $25,000 bond requirement for nonresident manufacturers, and the risk of product removal for paperwork or FDA-status issues. Retailers and distributors may also object to the inventory sell-off windows, seizure and forfeiture provisions, and escalating license suspensions. Supporters would likely emphasize enforcement, product traceability, and keeping unapproved vape products off the market, while critics may focus on market access, small-business impacts, and the breadth of state enforcement authority.